Skip to main content
DR REDDYS LABORATORIES LTD logo

DR REDDYS LABORATORIES LTD — Investor Relations & Filings

Ticker · RDY ISIN · US2561352038 LEI · 335800OVDPY3DVZR2798 BSE.NS Manufacturing
Open in API
Filings indexed 2,316 across all filing types
Latest filing 2026-05-12 Foreign Filer Report
Country IN India
Listing BSE.NS RDY

About DR REDDYS LABORATORIES LTD

https://www.drreddys.com/

Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company focused on providing affordable and innovative medicines. The company's core activities include the development, manufacturing, and marketing of a broad portfolio of products. This portfolio encompasses Active Pharmaceutical Ingredients (APIs), generic and branded-generic formulations, over-the-counter (OTC) products, and biologics. In addition to its significant presence in the generics market, the company invests in the research and development of novel molecules and proprietary products, with a focus on therapeutic areas such as dermatology and neurology. Dr. Reddy's is also committed to sustainable operations, actively working to reduce its environmental footprint through initiatives in water conservation, waste reduction, and decarbonisation.

Recent filings

Filing Released Lang Actions
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
Foreign Filer Report
2026-05-12 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a slide‐style presentation titled “Q4 & FY26 Results Update” containing detailed financial highlights, segment analyses, business updates, and non‐GAAP disclosures. It was filed under Regulation 30 as an investor deck for the company’s audited quarterly and full‐year results, fitting the definition of an “Investor Presentation.” It is not merely an announcement of a release (RPA) nor a terse earnings release (ER), but a full, multi‐slide investor presentation. Therefore, it is classified as IP.
2026-05-12 English
Investor presentation for Q4 and FY 2026 Audited Financial Results
Investor Presentation Classification · 95% confidence The document is a slide presentation titled “Q4 & FY26 Results Update,” containing detailed charts, segment‐level analyses, forward‐looking statements, business highlights, and strategic discussion. It was sent under SEBI Regulation 30 to NSE/BSE/NYSE as an enclosure. It goes well beyond a terse earnings release headline – it is a full investor presentation deck covering financials, business drivers, and outlook. Therefore, it fits the Investor Presentation category (IP).
2026-05-12 English
Investor presentation for Q4 and FY 2026 Audited Financial Results
Investor Presentation Classification · 88% confidence The document is a slide‐style presentation addressed under SEBI Regulation 30 enclosing the audited Q4 & FY26 financial results. It contains a Safe Harbor, charts, segment‐level metrics, business highlights, and strategic outlook—all hallmarks of an investor presentation deck. It is not merely a short notice of results nor a formal regulatory financial report; rather, it is a detailed presentation for investors.
2026-05-12 English
Recommendation of final dividend of INR Rs. 8/- per equity share for FY 2025-26
Interim / Quarterly Report Classification · 90% confidence The document is a formal exchange filing titled “Outcome of Board Meeting” by Dr. Reddy’s Laboratories, dated May 12, 2026. It contains approved audited financial results for the quarter and financial year ended March 31 2026, including full profit & loss tables, segment data, consolidated statements of financial position, and cash flows – actual financial statements, not just highlights or a link to a report. It is not a full Annual Report (10-K), nor merely an earnings press release with summary figures, nor an announcement that a report is attached. Instead, it provides comprehensive interim-period financial statements. Therefore, it fits the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-12 English
Change in Management
Board/Management Information Classification · 97% confidence The document is a disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing exchanges of Board meeting decisions: re-appointment of an Independent Director, appointment of another Independent Director, appointment/re-appointment of statutory and cost auditors, and elevation of a senior management personnel. It contains announcements of changes to the company's board and senior management rather than the full report itself. This corresponds to the Board/Management Information category.
2026-05-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.